Literature DB >> 23222689

Removal of valproic acid by plasmapheresis in a patient treated for multiple sclerosis.

D E T Bastiaans1, I W M van Uden, R A Ruiterkamp, B A de Jong.   

Abstract

We present a case of a patient with multiple sclerosis who was treated with plasmapheresis and valproic acid. We used therapeutic drug monitoring to determine whether plasma concentrations of valproic acid were kept within the therapeutic window and to determine the amount of valproic acid that was removed by plasmapheresis.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23222689     DOI： 10.1097/FTD.0b013e31827b1cfa

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN： 0163-4356            Impact factor:   3.681


  4 in total

Review 1.  Drug Dosing in Patients Undergoing Therapeutic Plasma Exchange.

Authors:  Sherif Hanafy Mahmoud; Jessica Buhler; Eric Chu; Suzie A Chen; Theresa Human
Journal:  Neurocrit Care       Date:  2021-02       Impact factor: 3.210

2.  Pathophysiological changes of inflammatory syndrome in multiple sclerosis after instituting therapeutic plasmapheresis.

Authors:  S Vlaic; V Poalelungi; M Bălăeţ; V L Purcărea; C Bălăeţ; B I Coculescu
Journal:  J Med Life       Date:  2017 Jan-Mar

3.  Effect of plasmapheresis on serum levels of clobazam, levetiracetam and topiramate.

Authors:  To Harmony Hau Man; Chang Richard Shek-Kwan; Chan Angel On-Kei; Chan Phoebe Wing Lam
Journal:  Epilepsy Behav Case Rep       Date:  2017-07-19

4.  Progressive multifocal leukoencephalopathy in an immunocompetent patient.

Authors:  Nicolien M van der Kolk; Peer Arts; Ingeborg W M van Uden; Alexander Hoischen; Frank L van de Veerdonk; Mihai G Netea; Brigit A de Jong
Journal:  Ann Clin Transl Neurol       Date:  2016-01-08       Impact factor: 4.511
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.